
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is in a strong financial position, and the potential risks associated with their gene therapy treatments such as potential equity dilution and a theoretical risk of tumorigenesis are being carefully monitored and investigated. The recent discovery of a tumor in a pediatric patient receiving their AAV-based therapy has not been conclusively linked to the treatment, and the patient has recovered without any negative effects. The company has a promising pipeline and is showing positive developmental advancements in their ongoing clinical trials.
Bears say
Regenxbio is a clinical-stage biotechnology company focused on developing gene therapy treatments for genetic defects and diseases using their NAV Technology Platform. However, numerous factors contribute to our negative outlook on the company, including uncertainties surrounding their product candidates, declining financials, patent expirations, potential competition, and manufacturing risks. These factors make us cautious about the company's future prospects and potential for success, leading us to have a negative outlook on the stock.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares